Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Nasopharyngeal Carcinoma 6Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Esophageal Squamous Cell Carcinoma 4Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Nasopharyngeal Neoplasms 2Uterine Cervical Dysplasia 1Solid Tumors 1Solid Tumor 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HCC 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Childhood Brain Stem Neoplasm 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Pancreatic Cancer 1Advanced Colorectal Cancer 1Advanced Cancer 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9pembrolizumab 8Laparoscopy 8Gastrectomy 8Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Ramucirumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × nimotuzumab × Clear all
NCT03400592 2018-01-17

NIEGA

Peking University

Phase 2 Unknown
55 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01180166 2013-09-19

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

ChineseAMS

Phase 2 Unknown
30 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡